"Buzz on the Street" Show: Q BioMed Inc. (OTCQB: QBIO) Announces FDA Approval | Financial Buzz

“Buzz on the Street” Show: Q BioMed Inc. (OTCQB: QBIO) Announces FDA Approval

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Q BioMed Announces FDA Approval.”

Q BioMed Inc. (OTCQB: QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company’s FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

In 2019, the American Cancer Society is estimating a total of 1.76 million new cancer cases and 606,880 cancer-related deaths in the U.S. The National Cancer Institute expects prostate, lung, breast, and colon/rectal cancer to account for the majority of the new estimated cases. Generally, most cancer patients undergo some type of therapy, whether it is chemotherapy or immunotherapy, and while these therapies can increase the survivability of a patient, there are several drawbacks. One of the most common symptoms associated with cancer therapy is chronic pain. Additionally, pain can also result from the cancerous tumor itself by pushing onto bones, nerves, or other organs. And according to Cancer Research UK, typically 30% to 60% of cancer patients deal with some sort of pain. Meanwhile, up to 90% of patients suffering from advanced cancer face similar pain management issues. Overall, the pain resulting from cancer can severely impact daily life activities such as typical day-to-day jobs, eating, and even sleeping. Most patients are also typically prescribed some sort of opioid-based painkillers, which is used to suppress the pain. However, opioids can also cause adverse effects; opioid painkillers such as morphine and oxycodone are commonly prescribed to cancer patients dealing with pain. Consequently, many patients tend to develop a dependency on opioids. Moreover, side effects associated with opioids includes dizziness, respiratory issues, and depression. And long-term effects can cause life-threatening issues to internal organs such as kidney failure. As a result, pharmaceutical companies have manufactured non-opioid or non-narcotics to help control or suppress pain. Some non-opioid medications can be purchased over-the-counter, however, stronger dosages may require a prescription. And according to data compiled by Mordor Intelligence, the global cancer therapy market was valued at USD 136.25 Billion in 2018. 

The American Cancer Society mentioned that patients should never accept pain as a normal part of having cancer. The organization said that patients should work with their medical physicians in order to control or lessen the pain as much as possible. Generally, the most common forms of pain are spinal cord compression and bone pain. Spinal cord compression is when a tumor spreads to the spine and presses onto the nerves of the spinal cord. Mild symptoms associated with spinal cord compression are usually back or neck pains. In severe instances, the matter can cause excruciating pain, numbness, or weakness in the arms and legs. The American Cancer Society stated that patients should immediately treat spinal cord compression because it can result in the loss of control over the bladder and bowels or ultimately even lead to paralyzation. On the other hand, bone pain is caused when cancer starts or spreads into the bones. Typically, treatment is aimed towards regulating cancer from affecting other parts of the body. Patients are often prescribed opioids as a common painkiller, but the adverse effects have prompted many to turn against the use of opioids. In fact, the National Cancer Institute highlighted that many oncology care providers relied heavily on opioids. Now, some primary care doctors no longer prescribe opioids, while some insurance companies have made it increasingly more difficult to obtain these medications. And as a result, more and more prescribers have been reluctant to introduce opioids and are now exploring different alternatives such as therapy or non-opioid drugs. “We providers have to educate our patients to help them understand that the role of opioids and other pain medications is to allow them to move and function better,” said the National Cancer Institute. “For some people, that may mean being able to walk around the block. For some, controlling the pain will allow them to return to work. And for those patients who are more fragile, the goal of pain medications may be to make them sufficiently comfortable to be able to hold their grandkids, or to sit comfortably on a hard chair in a church or restaurant.”

For more information, please visit: Q BioMed Inc.

For more corporate news on Q BioMed Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For q biomed inc., financial and corporate news dissemination, FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.